Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Oligodendroglioma 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Cancer Metastatic 1Leukemia, Megakaryoblastic, Acute 1Laryngeal Diseases 1

Interventions

sapanisertib 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Malignant Neoplasms of Digestive Organs × MLN 8237 × Clear all
NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡